Meeting
2019 Gastrointestinal Cancers Symposium
Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC).
Authors
Michael Sangmin Lee
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Michael Sangmin Lee , Sara R. Selitsky , Joel S. Parker , James Todd Auman , Yunhan Wu , Kelli Hammond , Bert O'Neil , Hanna Kelly Sanoff , Federico Innocenti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 597)
DOI
10.1200/JCO.2019.37.4_suppl.597
Abstract #
597
Poster Bd #
H20
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
First Author: Gregory Naylor
Poster
2018 Gastrointestinal Cancers Symposium
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
First Author: Guillem Argiles
Poster
2017 Gastrointestinal Cancers Symposium
Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database.
First Author: Alexis Diane Leal